# Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

> **NCT03866798** · PHASE4 · TERMINATED · sponsor: **Octapharma** · enrollment: 6 (actual)

## Conditions studied

- Chronic Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** Panzyga

## Key facts

- **NCT ID:** NCT03866798
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-21
- **Primary completion:** 2023-09-19
- **Final completion:** 2024-05-17
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** FDA released Octapharma from the pediatric post marketing requirement.
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866798, "Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03866798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*